Emil Kuriakose - 14 Jan 2026 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role: Chief Medical Officer
Signature: /s/ David Strauss, as Attorney-in-Fact for Emil Kuriakose
Issuer symbol: TERN
Transactions as of: 14 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 16 Jan 2026, 17:24:29 UTC
Previous filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kuriakose Emil	Chief Medical Officer	C/O TERNS PHARMACEUTICALS, INC., 1065 E. HILLSDALE BLVD., SUITE 100, FOSTER CITY	/s/ David Strauss, as Attorney-in-Fact for Emil Kuriakose	16 Jan 2026	0001892413

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TERN	Common Stock	Award	$0	+56,250	+112%	$0.000000	106,615	14 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TERN	Stock Option (Right to Buy)	Award	$0	+112,500		$0.000000	112,500	14 Jan 2026	Common Stock	112,500	$37.18	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
F2	25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.